Inspire Medical Systems (INSP) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this maker of devices for treating obstructive sleep apnea, should get reflected in its stock price. After all, empirical research shows a strong c ...

Inspire Medical Systems, Inc. (INSP) reported earnings per share of 32 cents for the second quarter of 2024 against the Zacks Consensus Estimate of a loss of 14 cents per share. In the year-ago period, the company had incurred a loss of 41 cents per share. Revenues in Detail Inspire Medical registered revenues of $195.9 million in the second quarter, up 29.8% year over year. The figure beat the Zacks Consensus Estimate by 3.7%. Segment Details Inspire Medical's operations consist of two geographic regions — ...

Inspire Medical Systems, Inc. (NYSE:INSP) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor Relations Tim Herbert - Chairman and Chief Executive Officer Rick Buchholz - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Richard Newitter - Truist Securities Adam Maeder - Piper Sandler Anthony Petrone - Mizuho Group Danielle Antalffy - UBS Michael Sarcone - Jefferies Chris Pasquale - Nephron Research Brett Fishbin ...

For the quarter ended June 2024, Inspire Medical Systems (INSP) reported revenue of $195.89 million, up 29.7% over the same period last year. EPS came in at $0.32, compared to -$0.41 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $195.9 million, representing a surprise of -0.01%. The company delivered an EPS surprise of +328.57%, with the consensus EPS estimate being -$0.14. While investors scrutinize revenue and earnings changes year-over-year and how they compare ...

Inspire Medical Systems (INSP) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 328.57%. A quarter ago, it was expected that this maker of devices for treating obstructive sleep apnea would post a loss of $0.63 per share when it actually produced a loss of $0.34, delivering a su ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q ________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 ______________________________ Inspire M ...

Exhibit 99.1 Inspire Medical Systems, Inc. Announces Second Quarter 2024 Financial Results and Updates 2024 Outlook Inspire Reports Year-over-Year Revenue Growth of 30% in the Second Quarter MINNEAPOLIS, MN - August 6, 2024 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter en ...

MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the FDA approval of the Inspire V therapy system which includes the next generation neurostimulator and the associated Bluetooth® patient remote and physician programmer. "We are thrilled to announce the FDA approval of our ...

MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the FDA approval of the Inspire V therapy system which includes the next generation neurostimulator and the associated Bluetooth® patient remote and physician programmer. "We are thrilled to announce the FDA approval of our ...

Key Takeaways TradingView Inspire Medical Systems released preliminary results indicated second-quarter and full-year revenue above analysts' estimates. The sleep apnea device maker expects second quarter sales to be 30% higher than a year ago. Inspire sees full-year revenue higher by 26% to 28% from 2023. Inspire Medical Systems (INSP) shares rose Monday after the maker of an implanted device to treat sleep apnea released preliminary results and updated guidance that beat forecasts. The company said it exp ...